Stefano Corda
About
Stefano Corda is a scholar working on Cardiology and Cardiovascular Medicine, Physiology and Molecular Biology.
According to data from OpenAlex, Stefano Corda has authored 43 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Cardiology and Cardiovascular Medicine, 7 papers in Physiology and 6 papers in Molecular Biology. Recurrent topics in Stefano Corda's work include Heart Failure Treatment and Management (19 papers), Cardiovascular Function and Risk Factors (8 papers) and Nitric Oxide and Endothelin Effects (7 papers). Stefano Corda is often cited by papers focused on Heart Failure Treatment and Management (19 papers), Cardiovascular Function and Risk Factors (8 papers) and Nitric Oxide and Endothelin Effects (7 papers). Stefano Corda collaborates with scholars based in Switzerland, United States and France. Stefano Corda's co-authors include David M. Stern, Jean‐Luc Wautier, Marie‐Paule Wautier, Ann Marie Schmidt, Olivier Chappey, Éric Vicaut, Christian Laplace, Jacques Duranteau, L. Rappaport and Jane‐Lise Samuel and has published in prestigious journals such as Circulation, Journal of Clinical Investigation and Circulation Research.
In The Last Decade
Stefano Corda
41 papers receiving 2.3k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Stefano Corda Switzerland | 20 | 625 | 613 | 545 | 498 | 394 | 43 | 2.3k | ||
| György Paragh Hungary | 29 | 682 1.1× | 547 0.9× | 433 0.8× | 318 0.6× | 401 1.0× | 136 | 2.7k | ||
| Dharambir K. Sanghera United States | 27 | 472 0.8× | 681 1.1× | 248 0.5× | 452 0.9× | 385 1.0× | 63 | 2.4k | ||
| Nigishi Hotta Japan | 28 | 461 0.7× | 693 1.1× | 431 0.8× | 868 1.7× | 676 1.7× | 100 | 3.3k | ||
| Jay C. Jha Australia | 21 | 512 0.8× | 902 1.5× | 225 0.4× | 519 1.0× | 453 1.1× | 38 | 2.5k | ||
| Maristela L. Onozato United States | 33 | 459 0.7× | 923 1.5× | 750 1.4× | 920 1.8× | 508 1.3× | 73 | 3.9k | ||
| Aino Soro‐Paavonen Finland | 23 | 551 0.9× | 602 1.0× | 597 1.1× | 402 0.8× | 1.0k 2.6× | 30 | 2.5k | ||
| M. E. Cooper Australia | 30 | 827 1.3× | 512 0.8× | 743 1.4× | 393 0.8× | 1.2k 3.0× | 52 | 3.0k | ||
| Nobuo Sakamoto Japan | 25 | 308 0.5× | 649 1.1× | 538 1.0× | 709 1.4× | 502 1.3× | 153 | 2.9k | ||
| Daisuke Kukidome Japan | 21 | 287 0.5× | 1.1k 1.7× | 232 0.4× | 570 1.1× | 364 0.9× | 30 | 2.2k | ||
| M. Rosca United States | 24 | 562 0.9× | 1.4k 2.3× | 538 1.0× | 631 1.3× | 263 0.7× | 33 | 2.5k |
Countries citing papers authored by Stefano Corda
Since
Specialization
Citations
This map shows the geographic impact of Stefano Corda's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stefano Corda with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stefano Corda more than expected).
Fields of papers citing papers by Stefano Corda
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Stefano Corda. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stefano Corda. The network helps show where Stefano Corda may publish in the future.
Co-authorship network of co-authors of Stefano Corda
This figure shows the co-authorship network connecting the top 25 collaborators of Stefano Corda. A scholar is included among the top collaborators of Stefano Corda based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stefano Corda. Stefano Corda is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Cohen‐Solal, Alain, Wendimagegn Alemayehu, Hiroyuki Tsutsui, et al.. (2025). Geographic Variation and Human Development Index in Heart Failure With Reduced Ejection Fraction. JACC Heart Failure. 13(9). 102548–102548.
2.
Westerhout, Cynthia M., Wendimagegn Alemayehu, Alain Cohen‐Solal, et al.. (2025). Geographic Region Variation in Patient Characteristics, Clinical Outcomes and Treatment of HFrEF in the VICTORIA Trial. ESC Heart Failure. 12(6). 3910–3919.
3.
Greene, Stephen J., et al.. (2025). Safety and Tolerability of a 5 mg Starting Dose of Vericiguat Among Patients with Heart Failure: The VELOCITY Study. European Journal of Heart Failure. 27(12). 2837–2840.
4.
Kittipibul, Veraprapas, Robert J. Mentz, Javed Butler, et al.. (2024). Projecting the Benefit of Vericiguat in PARADIGM-HF and DAPA-HF populations: Insights from the VICTORIA Trial. ESC Heart Failure. 12(2). 1479–1484.
5.
Reddy, Yogesh N.V., Javed Butler, Kevin J. Anstrom, et al.. (2024). Vericiguat Global Study in Participants with Chronic Heart Failure: Design of the VICTOR Trial. European Journal of Heart Failure. 27(2). 209–218.
6.
Ezekowitz, Justin A., Wendimagegn Alemayehu, Frank Edelmann, et al.. (2024). Diuretic Use and Outcomes in Patients with Heart Failure with Reduced Ejection Fraction: Insights from the VICTORIA Trial. European Journal of Heart Failure. 26(3). 628–637.
7.
Lahoz, Raquel, et al.. (2022). Recurrent heart failure hospitalizations increase the risk of mortality in heart failure patients with atrial fibrillation and type 2 diabetes mellitus in the United Kingdom: a retrospective analysis of Clinical Practice Research Datalink database. BMC Cardiovascular Disorders. 22(1). 234–234.
8.
Schlienger, Raymond G., et al.. (2022). Hospitalization Rates in Patients with Heart Failure and Reduced Ejection Fraction Initiating Sacubitril/Valsartan or Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers: A Retrospective Cohort Study. Cardiology and Therapy. 11(1). 113–127.
9.
Lahoz, Raquel, Clare Proudfoot, Stefano Corda, et al.. (2021). Burden and Quality of Life Among Female and Male Patients with Heart Failure in Europe: A Real-World Cross-Sectional Study. Patient Preference and Adherence. Volume 15. 1693–1706.
10.
Lindmark, Krister, Kurt Boman, Jan Stålhammar, et al.. (2021). Recurrent Heart Failure Hospitalizations Increase the Risk of Cardiovascular and All-Cause Mortality in Patients with Heart Failure in Sweden: A Real-World Study. ESC Heart Failure. 8(3). 2144–2153.
11.
Lahoz, Raquel, Clare Proudfoot, Stefano Corda, et al.. (2021). Caregivers of Patients with Heart Failure: Burden and the Determinants of Health-Related Quality of Life. Patient Preference and Adherence. Volume 15. 1153–1164.
12.
Proudfoot, Clare, et al.. (2021). Real-world effectiveness and safety of sacubitril/valsartan in heart failure: A systematic review. International Journal of Cardiology. 331. 164–171.
13.
Lahoz, Raquel, et al.. (2020). Recurrent Heart Failure Hospitalizations are Associated with Increased Cardiovascular Mortality in Patients with Heart Failure in Clinical Practice Research Datalink. ESC Heart Failure. 7(4). 1688–1699.
14.
Huusko, Jenni, Samuli Tuominen, Rachel Studer, et al.. (2020). Recurrent Hospitalizations are Associated with Increased Mortality Across the Ejection Fraction Range in Heart Failure. ESC Heart Failure. 7(5). 2406–2417.
15.
P., Thy, et al.. (2017). A Database Cohort Study to Assess the Risk of Angioedema Among Patients with Heart Failure Initiating Angiotensin-Converting Enzyme Inhibitors in the USA. American Journal of Cardiovascular Drugs. 18(3). 205–211.
16.
Jukema, J. Wouter, et al.. (2008). Negative effects of rofecoxib treatment on cardiac function after ischemia-reperfusion injury in APOE*3Leiden mice are prevented by combined treatment with thromboxane prostanoid-receptor antagonist S18886 (terutroban)*. Critical Care Medicine. 36(9). 2576–2582.
17.
Viles-González, Juan F., Valentı́n Fuster, Roberto Corti, et al.. (2005). Atherosclerosis regression and TP receptor inhibition: effect of S18886 on plaque size and composition—a magnetic resonance imaging study. European Heart Journal. 26(15). 1557–1561.
18.
Corda, Stefano, Jane‐Lise Samuel, & L. Rappaport. (2000). Extracellular Matrix and Growth Factors During Heart Growth. Heart Failure Reviews. 5(2). 119–130.
19.
Samuel, Jane‐Lise, Stefano Corda, Catherine Chassagne, & L. Rappaport. (2000). The Extracellular Matrix and the Cytoskeleton in Heart Hypertrophy and Failure. Heart Failure Reviews. 5(3). 239–250.
20.
Пили, Роберто, Stefano Corda, Antonino Passaniti, et al.. (1993). Endothelial cell Ca2+ increases upon tumor cell contact and modulates cell-cell adhesion.. Journal of Clinical Investigation. 92(6). 3017–3022.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by György Paragh Breakdown of academic impact, for papers by Dharambir K. Sanghera Breakdown of academic impact, for papers by Nigishi Hotta Breakdown of academic impact, for papers by Jay C. Jha Breakdown of academic impact, for papers by Maristela L. Onozato Breakdown of academic impact, for papers by Aino Soro‐Paavonen Breakdown of academic impact, for papers by M. E. Cooper Breakdown of academic impact, for papers by Nobuo Sakamoto Breakdown of academic impact, for papers by Daisuke Kukidome Breakdown of academic impact, for papers by M. Rosca